All In Biotech

Drug Trial Radar · NCT04775953

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus Bacteremia

Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Apr 22, 2021

Primary completion

Oct 6, 2023

Study completion Dec 1, 2023

Sponsor

Sponsor type
NIH
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with complicated bacteremia or right-sided native valve Infective Endocarditis (IE) caused by S. aureus who have cleared their baseline bacteremia. Approximately 200 subjects will be randomized 1:1 to receive either dalbavancin or a standard of care antibiotic regimen that is based upon the identification and antibiotic susceptibility pattern of the baseline organism. Subjects randomized to the dalbavancin treatment group will receive 2 doses of dalbavancin intravenously (IV) 1 week apart (1500 mg on Day 1 and Day 8 after randomization, with renal dose adjustment if appropriate). Subjects randomized to the standard of care antibiotic therapy treatment group will receive an antibiotic regimen considered to be standard of care based on the methicillin susceptibility pattern of the pathogen isolated at baseline for a duration of 4 to 6 weeks and up to 8 weeks for patients with vertebral osteomyelitis/discitis. The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at Day 70 of dalbavancin to that of standard of care antibiotic therapy used to consolidate therapy for the treatment of subjects with complicated S. aureus bacteremia in the intent-to-treat population (ITT).

Conditions

  • Staphylococcal Bacteraemia

Interventions

  • CefazolinDrug

    Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. Cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks)

  • DalbavancinDrug

    A second-generation lipoglycopeptide antibiotic synthesized from a fermentation product of Nonomuraea species

  • DaptomycinDrug

    Daptomycin (USA) or Cubicin (Spain) is a cyclic lipopeptide antibiotic that inhibits gram-positive bacteria. Daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks

  • NafcillinDrug

    Nafcillin is a semi-synthetic antibiotic related to penicillin. Nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks)

  • OxacillinDrug

    Oxacillin is an antibiotic used in resistant staphylococci infections. Oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks

  • VancomycinDrug

    Vancomycin is a glycopeptide antibiotic product of the organism Amycolatopsis orientalis. Vancomycin (dose per local standard of care × 4-6 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Desirability of Outcome Ranking (DOOR)Time frame: Day 70

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama Hospital - Infectious Diseases

    Birmingham, Alabama

  • University of California Davis Medical Center - Internal Medicine - Infectious Disease

    Sacramento, California

  • Harbor UCLA Medical Center - Medicine - Infectious Diseases

    Torrance, California

  • Torrance Memorial Medical Center

    Torrance, California

  • University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine

    Gainesville, Florida

  • University of South Florida Health - Internal Medicine

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Ochsner Health - Ochsner Medical Center - Department of Infectious Diseases

    New Orleans, Louisiana

  • Henry Ford Health System - Henry Ford Hospital

    Detroit, Michigan

  • Corewell Health - Infectious Disease

    Royal Oak, Michigan

  • University of Nebraska Medical Center - Infectious Diseases

    Omaha, Nebraska

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • New York Presbyterian Hospital - Weill Cornell Medical Center - Infectious Diseases

    New York, New York

  • SUNY Upstate Medical University - Infectious Disease Division

    Syracuse, New York

  • Atrium Health ID Consultants & Infusion Care Specialists

    Charlotte, North Carolina

  • Duke University Hospital - Infectious Diseases

    Durham, North Carolina

  • East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic

    Greenville, North Carolina

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Oregon Health and Science University - Adult Infectious Diseases Clinic

    Portland, Oregon

  • University of Pittsburgh - Medicine - Infectious Diseases

    Pittsburgh, Pennsylvania

  • Prisma Health - Greenville Health System - Infectious Disease

    Greenville, South Carolina

  • The University of Texas - MD Anderson Cancer Center - Infectious Diseases

    Houston, Texas

  • Carilion Roanoke Memorial Hospital

    Roanoke, Virginia

  • McGill University Health Centre

    Montreal, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.